Document:

EX-10.5

COOPERATION AGREEMENT

This Cooperation Agreement, dated as of June 18, 2012 (the “Effective Date”), is by and between

	 	(1)	 	EPICEPT CORPORATION, a corporation organized under the laws of the State of Delaware,
USA and having its principal offices at 777 Old Saw Mill Road, Tarrytown, New York 10591,
USA (“Corp”),

	 	(2)	 	EPICEPT GMBH, a corporation organized under the laws of Germany and having its
principal place of business at Gothestrasse 4, 80336 Munich Germany (“GmbH” and together
with Corp “EpiCept”);

	 	(3)	 	MEDA AB, a company incorporated in Sweden, with a registered office at Pipers Väg 2A,
Box 906 SE-170 09, Solna, Sweden “Meda”).

EpiCept and Meda are referred to in this Agreement, each as a “party” and, collectively, as the
“parties”.

Background

	 	A.	 	EpiCept and Meda entered into a Asset Purchase Agreement dated as of June 18 2012
(the “Asset Purchase Agreement”) pursuant to which Meda acquired the rights as, specified
therein, to assets relating to Ceplene.

	 	B.	 	In connection with the Asset Purchase Agreement, the parties will need to cooperate
with each other to give effect to the provisions of the Asset Purchase Agreement, in
particular through the provision by EpiCept of the transitional services as set out in
this Agreement.

	 	C.	 	EpiCept and Meda are willing to cooperate and provide each other with assistance, on
the terms and subject to the conditions set forth in this Agreement.

NOW THEREFORE, in consideration of the following mutual promises and obligations, and for other
good and valuable consideration the adequacy and sufficiency of which are hereby acknowledged, the
parties agree as follows:

1 DEFINITIONS

	1.1	 	Definitions. As used in this Agreement, terms defined in the preamble of this
Agreement shall have the meanings set forth therein and the following terms shall have the
meanings set forth below:

“Affiliate” shall mean any company or entity controlled by, controlling, or under common
control with a party hereto. For the purpose of this definition, a business entity shall be
deemed to “control” another business entity, if it owns directly or indirectly, more than
50% of the outstanding voting securities, capital stock, or other comparable equity or
ownership interest of such business entity, or exercises equivalent influence over such
entity.

“Agreement” means this Agreement and the Schedules hereto.

“AML Remission Treatment” shall mean the treatment of adult patients with acute myeloid
leukaemia in first remission concomitantly treated with interleukin-2 (IL-2).

“Ben Venue Agreement” means the agreement with Ben Venue Laboratories Inc as at Appendix 1.

“Ceplene” means any chemical composition comprising or containing histamine dihydrochloride
(2-(3H-imidazol-4-yl)ethylnamine dihydrochloride).

“Ceplene Assets” means all the assets transferred to Meda by EpiCept pursuant to the Asset
Purchase Agreement.

“Confidential Information” means any confidential and proprietary information and
materials, patentable or otherwise of a party (including, trade secrets, know-how,
inventions or discoveries, formulae, methods, materials, processes, techniques and
information relating to a party’s past, present and future marketing, financial, and
research and development activities of any product or potential product or useful technology
of the party and the pricing thereof in any form (written, oral, photographic, electronic,
magnetic, or otherwise), which is disclosed or made available by that party to the other
party or otherwise received or accessed by a party in the course of performing its
obligations or exercising its rights under this Agreement.

“Control” shall mean, with respect to any Information, patents or other intellectual
property rights, possession by a party of the right, power and authority (whether by
ownership, license or otherwise) to grant access to, to grant use of or to grant a license
or a sublicense to such Information, patents or intellectual property rights without
violating the terms of any agreement or other arrangement with any third party.

“Consultant” shall mean those individuals provided by EpiCept pursuant to Clause 4.1 to
perform the Transitional Services.

“Derivative” shall mean, with respect to Ceplene, any metabolite, prodrug, hydrate,
solvate, conjugate, salt, crystal form, ester, enantiomer, isomer or polymorph of Ceplene.

“EMA” means the European Medicines Agency or any successor entity thereof performing similar
functions.

“EpiCept Improvements” means Improvements developed, acquired or Controlled by or on behalf
of EpiCept or its Affiliates or sublicensees through its participation (if any) in the Post
Approval Commitments.

“EpiCept Retained Rights” means all Technology not otherwise sold to Buyer under the
Asset Purchase Agreement, including all EpiCept Improvements to the extent specifically
relating to the Product in the EpiCept Territory and EpiCept’s right in any Joint
Improvements, under the Control of EpiCept at the Effective Date or arising through its
participation (if any) in the Post Approval Commitments.

“EpiCept Territory” means all countries, excluding the Meda Territory.

“GMP” means current good manufacturing practice as promulgated under and in accordance with
the EMEA regulations and Commission Directive 2003/94/EC and applicable ICH guidelines as
each may be amended from time to time, or any successors thereto.

“Governmental Entity” means the United States or other country government, the government of
any of the states constituting the United States or any provinces or regions of any other
country, any municipality and any other national or provincial or regional government, and
all of their respective branches, departments, agencies, instrumentalities, non-appropriated
fund activities, subsidiary corporations or other subdivisions.

“Improvements” shall mean any and all developments, inventions or discoveries relating to
the Technology developed or acquired by, or under the Control of, a party and shall include
such developments intended to enhance the safety, efficacy or uses (including additional
indications) of the Product.

“Information” shall mean tangible and intangible techniques, technology, practices, trade
secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill,
experience, test data and results (including pharmacological, toxicological and clinical
test data and results), analytical and quality control data, results, descriptions and
compositions of matter.

“Intellectual Property Rights” means inventions, discoveries and/or improvements, patents,
patent applications, trademarks, trade names, service marks, copyrights, creative works,
derivative works, moral rights, trade secrets, proprietary information, rights to use,
industrial designs and other types of equivalent protection anywhere in the world and
proprietary materials (including chemical and biological materials).

“Joint Improvements” means Improvements developed, acquired or Controlled jointly by or on
behalf of the parties or their respective Affiliates or permitted sublicensees at the
Effective Date or arising through either party’s participation (if any) in the Post Approval
Commitments.

“Know-How” shall mean all Information owned or Controlled by a party that is necessary or
useful for the registration, development, promotion, marketing, sale or distribution of
Product.

“Marketing Authorisation” means the marketing authorisation in exceptional circumstances in
respect of Ceplene granted by the European Medicines Agency and the Orphan Drug Designation
for Ceplene.

“Meda Improvements” means Improvements developed, acquired or Controlled by or on behalf of
Meda, its Affiliates or sublicensees through its participation (if any) in the Post Approval
Commitments.

“Meda Pharma SARL” shall mean Meda Pharma SARL, a company incorporated under the laws of
Luxembourg (RC Luxembourg B157784) having its head office and registered address at 43
Avenue John Fitzgerald Kennedy, L-1855 Luxembourg, Grand-Duchy of Luxembourg

“Meda Territory” means the countries listed in Schedule 2.

“Meda Technology” means all Technology assigned by EpiCept to Meda pursuant to the Asset
Purchase Agreement together with all Meda Improvements to the extent specifically relating
to the Product and Meda’s right in any Joint Improvements, under the Control of Meda,
through its participation (if any) in the Post Approval Commitments, and the Trial Results.

“Patents” shall mean the patents set out in Schedule 3 and any patents owned or Controlled
by EpiCept or any of its Affiliates at the Effective Date, immediately prior to the
execution of the Asset Purchase Agreement, that, in the absence of a license thereunder,
would be infringed by the development, use, sale, offer for sale or import of Product in the
Meda Territory or EpiCept Territory or the manufacture of Ceplene or the Product anywhere in
the world.

“Person” means and includes an individual, a corporation, a partnership, a limited
liability company, a limited liability partnership, a joint venture, a trust, an
unincorporated association, a Governmental Entity or any other entity, wherever located or
organized.

“Pharmacovigilance Agreement” means the Pharmacovigilance Agreement effective April 1, 2010
between GmbH and Meda.

“Piramal Agreement” means the agreement with Piramal Healthcare (Canada) Limited as at
Appendix 2.

“Post Approval Commitments” means the post approval commitments regarding clinical studies
EpiCept agreed to undertake, as set out in the grant of the Marketing Authorisation, dated
24 July 2008.

“Product” means a pharmaceutical product that is or contains (i) Ceplene and/or (ii) if
relating to AML Remission Treatment only, Ceplene or a Derivative, and, in both cases, line
and label extensions thereof, including all formulations, routes of administration and other
Improvements made or acquired by EpiCept, in all cases, whether administered alone or in
combination with other pharmaceutical products or active pharmaceutical ingredients.

“Regulatory Authority” shall mean any country, federal, supranational, state or local
regulatory agency, department, bureau, court or other governmental or regulatory authority
having the authority to regulate the development or marketing of pharmaceutical products in
the Territory or any part thereof (e.g. the EMEA).

“Technology” shall mean the Patents and the Know How.

“Transitional Period” means the period commencing on the Effective Date and ending on the
fifth (5th) year anniversary of the Effective Date.

“Transitional Services” means the transitional services set out in Schedule 1 to this
Agreement.

“Trial” means the clinical trial “An open label, multicenter study of the effects of
remission maintenance therapy with Ceplene (Histamine Dihydrochloride), given in conjunction
with low-dose Interleukin-2 (IL2, Proleukin), on immune response and minimal residual
disease (MRD) in adult patients with acute myeloid leukaemia (AML) in first complete
remission (CR1)” (Protocol EPC2008-02).

“Trial Results” means the results of the Trial supplied by ICON Clinical Research Limited
(“ICON”) to Meda pursuant to a services agreement dated 2 April 2009 between Corp and ICON,
under which ICON conducts the Trial, such agreement being assigned to Meda pursuant to the
Asset Purchase Agreement.

	1.2	 	Rules of Construction.

	 	 	 	References in this Agreement to any gender shall include references to all genders.

	 	 	 	Unless the context otherwise requires, references in the singular include references in the
plural and vice versa.

	 	 	 	References to a party to this Agreement or to other agreements described herein means those
Persons executing such agreements.

	 	 	 	The words “include”, “including”, “includes” or “in particular” shall be deemed to
be followed by the phrase “without limitation” or the phrase “but not limited to” in
all places where such words appear in this Agreement.

	 	 	 	This Agreement is the joint drafting product of EpiCept and Meda and each provision
has been subject to negotiation and agreement and shall not be construed for or against
either party as drafter thereof.

2 TECHNOLOGY COOPERATION

	2.1	 	Licences. The parties hereby grant the following licences:

	 	 	 	EpiCept hereby grants to Meda an exclusive, perpetual, royalty free, licence under the
EpiCept Retained Rights to develop, use, sell, have sold, offer for sale, import,
register, promote, market and distribute Products in the Meda Territory. This licence
shall include the right to grant and authorize sublicences (the “EpiCept Licence”);
and

	 	 	 	Meda hereby grants to EpiCept an exclusive, perpetual, royalty free, licence under
the Meda Technology to develop, use, sell, have sold, offer for sale, import, register,
promote, market and distribute Products in the EpiCept Territory. This licence shall
include the right to grant and authorize sublicences (the “Meda Technology Licence”).

	 	 	 	EpiCept hereby grants to Meda a non-exclusive, perpetual, royalty free, licence under the
EpiCept Retained Rights to make or have made Ceplene or Products anywhere in the world
for the sale of such Ceplene or Products in the Meda Territory. This licence shall
include the right to grant and authorize sublicences, without further reference to
EpiCept (the “EpiCept Manufacturing Licence”); and

	 	 	 	Meda hereby grants to EpiCept a non-exclusive, perpetual, royalty free, licence
under the Meda Technology to make or have made Ceplene or Products anywhere in the
world for the sale of such Ceplene or Products in the EpiCept Territory. This licence
shall include the right to grant and authorize sublicences, without further reference
to Meda (the “Meda Manufacturing Licence”).

	2.2	 	Cooperation. On written request each party shall provide the other with all
information, and copies of such documentation, as may reasonably be requested by the other
party in relation to exercising its rights under respectively the EpiCept Licence, Meda
Technology Licence, EpiCept Manufacturing Licence or the Meda Manufacturing Licence.

	2.3	 	Exclusion. Save as expressly set out in this Clause 2 or Clause 3 neither party
grants to the other party any right, interest or licence in respect of its Intellectual
Property Rights, including, for the avoidance of doubt, any Improvements or Know How arising
after the Effective Date.

	2.4	 	Disclaimer. Except as expressly set forth in this Agreement, THE EPICEPT RETAINED
RIGHTS AND MEDA TECHNOLOGY RIGHTS PROVIDED HEREUNDER ARE PROVIDED “AS IS,” AND EACH PARTY
EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT
LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A
COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN CONNECTION WITH CEPLENE OR THE PRODUCTS.

3 SUPPLY AND REGULATORY COOPERATION

	3.1	 	Ceplene Supply Obligations. At EpiCept’s request Meda shall, during the Transitional
Period only use its commercially reasonable efforts to supply to EpiCept, Ceplene or Product
supplied to Meda by Ben Venue under the purchase order assigned to Meda pursuant to the Asset
Purchase Agreement or from Meda’s qualified, EU-approved Ceplene or Product manufacturer
subject to the following:

	 	 	 	The supply shall be at Meda’s fully allocated cost of goods to Meda plus forty
percent (40%), with payment to be made before any product is ordered from a Third Party
by Meda (or shipped to EpiCept if already in stock with Meda). Meda shall be under no
further obligation under this Section 3.1 until payment is received.

	 	 	 	Subject to the other provisions of this Section 3.1:

	 	3.1.1.1	 	Where supply is made from Ceplene or Product supplied to Meda by EpiCept
under the Asset Purchase Agreement it shall be made on the same terms and
subject to the same rights and obligations assigned to Meda under the
relevant contracts assigned to Meda under the Asset Purchase Agreement; and

	 	3.1.1.2	 	Where supply is from Ceplene or Product supplied to Meda under agreements
with any other manufacturer, it shall be made on terms and conditions as if
EpiCept were assigned Meda’s rights and obligations under the relevant
supply agreement.

	 	 	 	EpiCept shall not be entitled to acquire any of Meda’s EU QP released stocks of Ceplene or
Product transferred to Meda under the Asset Purchase Agreement.

	 	 	 	Meda’s obligation to use commercially reasonable efforts to supply Ceplene or Product that
is manufactured after the Effective Date will be subject to the following:

	 	3.1.1.3	 	EpiCept shall give Meda as much notice of its requirements as reasonably
possible. Where, in Meda’s absolute discretion it considers that it has
sufficient stock of Ceplene or Product on hand to meet EpiCept’s requirement
without compromising its own requirements for Ceplene or Product (including
the holding of a sufficient safety stock), Meda may supply Ceplene or
Product from its inventory;

	 	3.1.1.4	 	the cost of supply shall be Meda’s fully allocated cost of goods plus
forty percent (40%), such payment to be made in advance of Meda placing an
order with any supplier;

	 	3.1.1.5	 	Meda shall use its commercially reasonable efforts (subject to any
limitations on Meda and compliance with any forecasting provisions) to
include EpiCept’s requirements in the next order Meda makes following the
receipt of a contractually binding request and payment from EpiCept. It
shall be in Meda’s absolute discretion whether it shall make a separate
order on behalf of EpiCept; and

	 	3.1.1.6	 	Whilst Meda shall make available a copy of any related manufacturing,
testing and QP release records Meda has in it is possession, Meda shall have
no responsibility whatsoever for the release of Ceplene or Product for the
markets where the relevant product is to be used of the Ceplene or Licensed
Products to be supplied to EpiCept hereunder.

	 	 	 	All Ceplene and Products supplied under this Agreement are supplied on an “as is”
basis and Meda shall have no liability whatsoever for delays or defects in any products
supplied under this Agreement or for any acts or omissions of Piramal Healthcare
(Canada) Limited’s, Ben Venue Laboratories, or any other manufacturer from which Meda
orders Ceplene or Products on EpiCept’s behalf, including, in respect of any failure to
supply or for defects in materials supplied. Meda’s entire liability for a particular
shipment of Ceplene or Product supplied shall be limited to the payment received by
Meda in respect of the amount supplied, or to be supplied, to EpiCept in that shipment.

	 	 	 	Meda shall use its commercially reasonable efforts provide reasonable assistance, at
EpiCept’s cost, to seek to enable an agreement to be entered into between EpiCept and
any third party manufacturer of Ceplene engaged by Meda and holding a GMP licence
approved by the European Medicines Agency.

	 	 	 	In any case all supply of Ceplene and Product shall be deemed to have taken place
outside the Meda Territory and is subject to the condition that any materials so
provided to EpiCept may only be used, sold or delivered in the EpiCept Territory.

	 	 	 	At EpiCept’s reasonable request within the last year of the Transitional Period,
Meda shall meet with EpiCept to discuss the continued supply of Ceplene and/or Product
to EpiCept provided always that any obligation to continue to supply shall be in Meda’s
absolute discretion and subject to the signature of a written supply agreement between
the Parties.

	3.2	 	Supporting Information for Ceplene Supply Obligations. On reasonable request by
EpiCept (such request stating what information is required in reasonable detail), Meda shall,
at EpiCept’s reasonable cost, provide or seek to procure that EpiCept shall receive a copy of
relevant related information in respect of any Ceplene or Product EpiCept acquires pursuant to
Clause 3.1, including copies any applicable GMP supporting documents such as batch records,
packaging records, QP release documents, certificates of analysis and stability data for
purposes of facilitating compliance with applicable GMP regulations by EpiCept or its actual
or potential licensees of Ceplene in the EpiCept Territory.

	3.3	 	Regulatory Filing Cooperation. The parties shall provide each other with information
relating to any filings by the relevant party, its Affiliates or licensees relating to Ceplene
or Product with any Regulatory Authority inside or outside its exclusive territory, including,
in connection with:

	 	 	 	the Post-Approval Commitments;

	 	 	 	any serious adverse events, periodic safety update reports or chemistry;
manufacturing and control data;

	 	 	 	all variations to any Regulatory Approvals for Ceplene; and

	 	 	 	any other Information which may reasonably be required for submission to a
Regulatory Authority.

	3.4	 	Pharmacovigilance Cooperation. The parties shall collect and exchange
pharmacovigilance data regarding the Product sufficient to permit each party to comply with
its regulatory and other legal obligations in its respective exclusive territory pursuant to
the Pharmacovigilance Agreement, which shall remain in full force and effect.

4 TRANSITIONAL SERVICES

	4.1	 	Transitional Services. EpiCept shall provide to Meda such Transitional Services, as
may be requested in writing by Meda from time to time during the Transitional Period. All
Transitional Services shall be performed on a consultancy basis by Consultants provided by
EpiCept.

	4.2	 	Diligence. EpiCept shall procure that each Consultant shall:

	 	 	 	possess sufficient, experience, knowledge and skills to perform the Transitional Services;

	 	 	 	co-operate with Meda and comply with all reasonable requests and instructions provided by
Meda from time to time;

	 	 	 	 	 
	 	5	 	 	provide all assistance and knowledge that is reasonably requested of him or her; and

use all reasonable skill and care in promptly supplying the Transitional Services; and

comply with all applicable laws and regulations.

CONSIDERATION FOR TRANSITIONAL SERVICES

	5.1	 	Consideration for Transitional Services. In consideration of the supply by EpiCept of
the Transitional Services, Meda shall pay EpiCept for the time spent by the Consultant(s) in
providing the Transitional Services. The rate payable for the Consultant’s time shall be
calculated at the rate of two hundred fifty US dollars (US$250) per hour per Consultant, up to
an aggregate of two thousand US dollars (US$2,000) per day per Consultant (the “Charges”).

	5.2	 	VAT. The Charges are exclusive of any value added tax or other applicable taxes or
duties (except corporation tax or other taxes on profit), for which Meda shall be additionally
liable.

	5.3	 	Invoicing. EpiCept shall invoice the Charges to Meda on a monthly basis in arrears,
each invoice itemising the Charges for each Transitional Service and the value added tax
thereon (if applicable). Where third party costs in excess of one thousand US dollars
(US$1,000) per service need to be incurred to complete the Transitional Services, EpiCept
shall seek the prior written consent of Meda, only those third party costs consented to in
advance by Meda in writing may be recharged, at cost price, to Meda. The invoice shall detail
any such third party costs and the basis of apportionment (if any). Meda shall pay the Charges
within forty five (45) days of the date of receipt of the relevant invoice.

	5.4	 	Records. EpiCept shall:

	 	 	 	keep, or procure that there are kept on its behalf, true and accurate records and
accounts of all Transitional Services rendered, and third party costs incurred, in
sufficient detail to enable the amount of the Charges to be verified by Meda; and

	 	 	 	no later than five (5) days after any request made, from time to time, by Meda,
provide to Meda or its agent copies of the records and accounts referred to in Clause
5.4.1.

6 GENERAL COOPERATION

	6.1	 	Further Assurance. EpiCept and Meda will use all reasonable efforts to take, or cause
to be taken, all actions and to do, or cause to be done, all things, necessary, proper or
advisable under applicable laws to consummate and make effective the transfer of the Trial and
the Ceplene Assets. In particular, each party shall do, or procure the doing of, all acts and
things, and execute, or procure the execution of, all documents, as may reasonably be required
to give full effect to this the transfer of the Trial and the Ceplene Assets and the
provisions of this Agreement.

7 CONFIDENTIALITY

	7.1	 	Confidentiality Undertaking. Either party shall not, directly or indirectly,
publish, disseminate or otherwise disclose, deliver or make available to any person outside
its organisation any of the other party’s Confidential Information or use the other party’s
Confidential Information for any purpose other to exercise its rights as set out in this
Agreement without the prior written consent of the other party.

	7.2	 	Permitted Disclosure. Either party may disclose the other party’s Confidential
Information to its representatives who need to receive such Confidential Information pursuant
to enable the disclosing party to exercise its rights pursuant to this Agreement provided such
representatives are bound to protect such Confidential Information by obligations of
confidentiality, non-disclosure and non-use at least as stringent as those contained in this
Agreement.

	7.3	 	Exclusions. The above provisions of confidentiality, non-disclosure and non-use will
not apply to that part of the Confidential Information, which the receiving party is able to
demonstrate by documentary evidence:

	 	 	 	was fully in possession of the receiving party prior to receipt from the disclosing
party and was not acquired directly or indirectly from the disclosing party or any of
its representatives;

	 	 	 	was in the public domain at the time of receipt from the disclosing party; or
becomes part of the public domain through no fault of the receiving party or any of its
representatives;

	 	 	 	is lawfully received by the receiving party on a non-confidential basis from a
third party having a right of further disclosure;

	 	 	 	is developed by the receiving party without reference to the disclosing party’s
Confidential Information; or

	 	 	 	is required by any applicable laws or regulatory body to be disclosed, provided
that the party required to make the disclosure provides prior written notice of such
disclosure to the other party, to the extent legally permissible, and limits disclosure
to that portion of the Confidential Information which it is legally required to
disclose.

8 MISCELLANEOUS

	8.1	 	Headings and References. The headings in this Agreement are for convenience of
reference only and shall not affect its interpretation. Any reference in this Agreement to a
Clause, Schedule or Appendix, unless it clearly refers to another instrument, means the
specified Clause, Schedule or Appendix of this Agreement.

	8.2	 	Severability. The provisions of this Agreement shall be deemed severable and the
invalidity or unenforceability of any provision shall not affect the validity or
enforceability of the other provisions hereof. If any provision of this Agreement, or the
application thereof to any Person or any circumstance, is invalid or unenforceable, (a) a
suitable and equitable provision shall be substituted therefor in order to carry out, so far
as may be valid and enforceable, the intent and purpose of such invalid or unenforceable
provision and (b) the remainder of this Agreement and the application of such provision to
other Persons, entities or circumstances shall not be affected by such invalidity or
unenforceability.

	8.3	 	Expenses. Except as otherwise expressly provided herein, each of EpiCept and Meda
shall be responsible for its own expenses whether or not the Transactions are consummated.

	8.4	 	Notices. Any notice to be given under this Agreement must be in writing and
delivered either in Person, by any method of mail (postage prepaid) requiring return receipt,
or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the
party to be notified at its address(es) given below, or at any address such party has
previously designated by prior written notice to the other. Notice shall be deemed
sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt;
(b) if mailed, five (5) days after the date of postmark; or (c) if delivered by express
courier, the next business day the courier regularly makes deliveries in the country of the
recipient.

If to Meda, to:

Meda AB

Pipers Väg 2A

Box 906 SE-170 09

Solna, Sweden

Facsimile: +46 8 630 1919

Attention: Anders Lönner

With a copy to:

Reed Smith LLP

The Broadgate Tower

20 Primrose Street

London EC2A 2RS England

Attention: John Wilkinson, Esq.

Telephone: +44(0)2031163640

Facsimile: +44(0)2031163999

If to EpiCept to:

EpiCept Corporation

777 Old Saw Mill Road

Tarrytown, NY  10591 USA

Attention: Jack Talley

Telephone: +1-914-606-3500

Facsimile: +1-914-606-3501

With a copy to:

Eilenberg & Krause LLP

11 East 44th Street, 19th Floor

New York, New York 10017 USA

Attention: Adam Eilenberg, Esq.

Telephone: +1-212-986-9700

Facsimile: +1-212-986-2399

	8.5	 	Waiver; Consents. The failure by any party to exercise any right under, or to object
to the breach by any other party of any term, provision or condition of, this Agreement shall
not constitute a waiver thereof and shall not preclude such party from thereafter exercising
that or any other right, or from thereafter objecting to that or any prior or subsequent
breach of the same or any other term, provision or condition of the Agreement. Any consent
granted pursuant to this Agreement shall be in writing, executed by the Person authorized by
the consenting party to receive notices, and shall be a consent only to the transaction, act
or agreement specifically referred to in the consent and not to other similar transactions,
acts or agreements.

	8.6	 	Assignment. This Agreement shall not be assigned by any party without the prior
written consent of the other party, provided however, that:

	 	 	 	Meda Pharma SARL shall be entitled to the benefit of this Agreement equally with
Meda;

	 	 	 	Meda may assign this Agreement to any Affiliate of Meda; and

	 	 	 	Either Party may assign the benefit and burden of this Agreement to any acquiror of all or
substantially all of the business or assets to which this Agreement relates if such
acquiror confirms and acknowledges the obligations of the assigning Party under this
Agreement.

Any attempted assignment in contravention with the foregoing shall be void. This Agreement
shall be binding on and inure to the benefit of the parties hereto, their successors and any
permitted assigns.

	8.7	 	Governing Law. This Agreement and any disputes, claims, or actions related thereto
shall be governed by and construed in accordance with the laws of the State of New York, USA,
without regard to the conflicts of laws provisions thereof with the exceptions of Sections
5-1401 and 5-1402 of the New York General Obligations Law.

	8.8	 	Parties Interest. This Agreement is binding upon and shall inure to the benefit of
the parties hereto and their successors and permitted assigns. Nothing contained in this
Agreement, express or implied, shall give any other Person any legal or equitable right,
remedy or claim under or with respect to this Agreement except as expressly provided.

	8.9	 	Dispute Resolution. Any dispute arising under or relating to the parties rights and
obligations under this Agreement will be referred to the Chief Executive Officer of Corp and
the Chief Executive Officer of Meda for resolution (the “Authorized Officers”). Each
Authorized Officer shall appoint two additional authorized representatives of such party to
serve as a member of a Dispute Resolution Committee (the “DRC”). In the event of a dispute,
the DRC shall meet and attempt, in good faith, to resolve such dispute. If the DRC is unable
to resolve such dispute within thirty (30) days of such dispute being referred to them, then,
upon the written request of either party to the other party, the dispute shall be subject to
arbitration, as provided in Section 8.10.

	8.10	 	Arbitration.

	 	 	 	Claims. Any claim, dispute, or controversy of whatever nature arising out of or
relating to this Agreement that is not resolved pursuant to Section 8.9 within the
required thirty (30) day period, including without limitation, any action or claim
based on tort, contract, or statute, or concerning the interpretation, effect,
termination, validity, performance and/or breach of this Agreement (“Claim”), shall be
resolved by final and binding arbitration before a panel of three neutral experts with
relevant industry experience. The arbitration proceeding shall be administered by the
American Arbitration Association (the “AAA”) in accordance with its then existing
International Arbitration Rules, and the panel of arbitrators shall be selected in
accordance with such rules. The arbitration shall be conducted in English, and shall be
held in New York, New York, USA.

	 	 	 	Arbitrators’ Award. The arbitrators shall, within fifteen (15) days after the
conclusion of the arbitration hearing, issue a written award and statement of decision
describing the essential findings and conclusions on which the award is based,
including the calculation of any damages awarded. The decision or award rendered by the
arbitrators shall be final and non-appealable, and judgment may be entered upon it in
any court of competent jurisdiction. The arbitrators shall be authorized to award
compensatory damages, but shall NOT be authorized (i) to award non-economic damages,
(ii) to award punitive damages, or (iii) to reform, modify or materially change this
Agreement or any other agreements contemplated hereunder; provided, however, that the
damage limitations described in parts (i) and (ii) of this sentence will not apply if
such damages are statutorily imposed.

	 	 	 	Costs. Each party shall bear its own attorneys’ fees, costs, and disbursements
arising out of the arbitration, and shall pay an equal share of the fees and costs of
the arbitrators; provided, however, the arbitrators shall be authorized to determine
whether a party is the prevailing party, and at their discretion, to award to that
prevailing party reimbursement for its reasonable attorneys’ fees, costs and
disbursements (including, for example, expert witness fees and expenses, photocopy
charges and travel expenses), and/or the reasonable fees and costs of the AAA and the
arbitrators.

	8.11	 	Court Actions. Nothing contained in this Agreement shall deny either party the right
to seek injunctive or other equitable relief from a court of competent jurisdiction in the
context of a bona fide emergency or prospective irreparable harm, including without limitation
relating to the violation of the confidentiality provisions of Section 7.1 hereof, and such an
action may be filed and maintained notwithstanding any ongoing arbitration proceeding. In
addition, either party may bring an action in any court of competent jurisdiction to resolve
disputes pertaining to the validity, construction, scope, enforceability, infringement or
other violations of Patents or other intellectual property rights, and no such matter shall be
subject to arbitration pursuant to Section 8.10.

	8.12	 	Continued Performance. The parties agree to continue performing under the Agreement
in accordance with its provisions, pending the final resolution of any dispute.

	8.13	 	Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but such counterparts shall together constitute one and the
same Agreement.

	8.14	 	Entire Agreement; Amendments. This Agreement constitutes the entire understanding
among the parties hereto with respect to the subject matter contained herein and supersedes
any prior understandings and agreements among them respecting such subject matter. This
Agreement may be amended, supplemented, and terminated only by a written instrument duly
executed by EpiCept and Meda. Each of Meda and EpiCept recognizes that the liability and
remedy provisions of this Agreement are material to the Agreement and have been bargained for
and are reflected in the mutual promises and agreements set forth in the Agreement.

1

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly
authorized officers on the date first above written.

	 	 	 
	EPICEPT

EPICEPT CORPORATION

By:       

Name:       

Title:      

	 	EPICEPT GMBH

By:      

Name:      

Title:      

	MEDA AB

By:      

Name:      

Title:      

	 	

2

SCHEDULE 1

TRANSITIONAL SERVICES

Transitional Service / Description

Manufacturing Support

Supporting the transition of manufacturing from third party
suppliers to Meda or other third party suppliers of Meda’s
choosing.

Transfer of the Trial and Post Approval Commitments

Supporting the transfer of the Trial to Meda. In particular:

(i) assisting with all regulatory filings to enable Meda to
take on the role of sponsor of the Trial; and

(ii) assisting with the transfer of site agreements, in
respect of the Trial, to Meda.

Transfer of Marketing Authorisation

Supporting the transfer to Meda of the Marketing
Authorisation. In particular, assisting with all regulatory
filings in respect of such transfer provided always that this
shall not reduce or remove EpiCept’s obligations under any
further assurance clauses in the Asset Purchase Agreement
(including Sections 5.9 and 8.7 of the Asset Purchase
Agreement) or this Agreement (including Clause 6.1 of this
Agreement).

Transfer of Ceplene Assets

Supporting the transfer of the Ceplene Assets to Meda, to
ensure that Meda obtains and can exercise all rights in
respect of the Ceplene Assets. In particular, transferring
such technical know-how as is required to enable Meda to
exploit the Ceplene Assets provided always that this shall
not reduce or remove EpiCept’s obligations under any further
assurance clauses in the Asset Purchase Agreement (including
Sections 5.9 and 8.7 of the Asset Purchase Agreement) this
Agreement (including Clause 6.1 of this Agreement) or any of
the agreements assigning any patents, trademarks or other
intellectual property to Meda or any of its Affiliates.

3

SCHEDULE 2

MEDA TERRITORY

	 	 	 
	Europe
	Albania

Andorra

Austria

Belarus

Belgium

Bosnia-Herzegovina

Bulgaria

Croatia

Cyprus

Czech Republic

Denmark

Estonia

Finland

Former Yugoslav Republic of Macedonia

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

	 	Liechtenstein

Lithuania

Luxembourg

Malta

Moldova

Monaco

Montenegro

Norway

Poland

Portugal

Romania

Russia

San Marino

Serbia

Slovakia

Slovenia

Spain

Sweden

Switzerland

The Netherlands

The United Kingdom

Turkey

Ukraine

Vatican City
	 

	 	 
	Other Countries

	 

	Australia

Georgia

Hong Kong

India

Indonesia

People’s Republic of China

Philippines

Qatar

Republic of China (Taiwan)

Saudi Arabia

Singapore

South Korea

Thailand

United Arab Emirates

	 	Japan

Kuwait

Malaysia

New Zealand

Oman

Pakistan

	 

	 	 

4EX 10.1 2012  Corporate Incentive Plan

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

		
	1.
	PURPOSE

The purpose of the Motricity, Inc. (the “Company”) Corporate Incentive Plan (the “Plan”) is to drive a culture focused on organizational performance.  The Plan is intended to deliver “pay-for-performance” through annual incentive payments based on overall Company performance.  The Plan is intended to provide all eligible employees (the “Participants”) with additional compensation for their contribution to the achievement of the Company’s objectives, encouraging and stimulating superior performance by such individuals, and assisting and retaining highly qualified employees. 

		
	2.
	    DEFINITIONS

Definitions for specific terms used within this Plan document are identified below.

		
	A.
	“Affiliate” means each of the following:  (a) any Subsidiary; (b) any Parent; (c) any corporation, trade or business (including, without limitation, a partnership or limited liability company) which is directly or indirectly controlled 50% or more (whether by ownership of stock, assets or an equivalent ownership interest or voting interest) by the Company or one of its Affiliates; (d) any trade or business (including, without limitation, a partnership or limited liability company) which directly or indirectly controls 50% or more (whether by ownership of stock, assets or an equivalent ownership interest or voting interest) of the Company; and (e) any other entity in which the Company or any of its Affiliates has a material equity interest and which is designated as an “Affiliate” by resolution of the Compensation Committee.

		
	B.
	“Base Salary” refers to the annual salary, or base wage in the case of hourly employees, component of the employee’s compensation as specified in their employment agreement or offer letter as adjusted from time to time, exclusive of any additional allowances, payments or non-cash benefits.

		
	C.
	“Board” means the Board of Directors of the Company.

		
	D.
	“Bonus Award” is the cash payment that may be earned by a Participant, subject to the terms and conditions of the Plan.

		
	E.
	“Bonus Pool” is a pool of funds established in the Budget from which Bonus Awards may be paid subject to the terms and conditions hereof.  The funding of the Bonus Pool will be determined and calculated in accordance with Exhibit A. 

F.“Budget” means the Company’s Fiscal Year budget as approved by the Board.

		
	G.
	“Cause” means with respect to a Participant’s termination, the Participant’s: (i) failure to perform  his or her duties; (ii) commission of, or indictment for a felony or any crime involving fraud or embezzlement or dishonesty or conviction of, or plea of nolo contendere to a misdemeanor (other than a traffic violation) punishable by imprisonment under federal, state or local law; (iii) engagement in an act of fraud or of willful dishonesty towards the Company or any of its Affiliates; (iv) misconduct or negligence while 

1

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

employed by the Company or any of its Affiliates; (v) violation of a federal or state securities law or regulation or employment law; (vi) dishonesty detrimental to the Company or any of its Affiliates; (vii) conduct involving any immoral acts which is reasonably likely to impair the reputation of the Company or any of its Affiliates; (viii) disloyalty to the Company or any of its Affiliates; (ix) use of a controlled substance without a prescription or the use of alcohol which impairs Participant’s ability to carry out Participant’s duties and responsibilities; (x) violation by a Participant of the Company’s policies and procedures or any breach of any agreement between the Company and Participant; or (xi) embezzlement and/or misappropriation of property of the Company or any of its Affiliates. 
		
	H.
	“CEO” means the Company’s Chief Executive Officer.

		
	I.
	“Code” means the Internal Revenue Code of 1986, as amended.  Any reference to any section of the Code shall also be a reference to any successor provision and any Treasury Regulation promulgated thereunder.

		
	J.
	“Company” means Motricity, Inc. and, if applicable, any of its subsidiaries and their successors and assigns.

		
	K.
	“Compensation Committee” means the Compensation Committee of the Board, which has the authority to oversee the Plan and approve and amend the Plan if it deems such change(s) is/are in the best interest of the Company.

		
	L.
	“Eligible Earnings” will be equal to the Participant’s actual cumulative payments of Base Salary for the Fiscal Year, or specified portion thereof. Eligible Earnings is determined before reductions for contributions under Section 401(k) of the Internal Revenue Code of 1986, as amended, and includes (but is not limited to) regular earnings, holiday pay, paid time off, sick pay, on call pay, call out pay and short term disability. As defined, Eligible Earnings effectively prorates the effect of any changes in Base Salary during the Fiscal Year for purposes of calculating Bonus Awards. Eligible Earnings does not include, without limitation and to the extent applicable, (i) financial awards under the Plan; (ii) variable compensation such as incentive awards, commissions or spot bonuses if any; (iii) imputed income from such programs as life insurance, auto allowance, or non-recurring earnings such as moving or relocation expenses, allowances or perquisites; (iv) stock-related compensation; or (v) overtime, unless required to be included in Eligible Earnings for purposes of the Plan, in accordance with applicable law. 

		
	M.
	“EBITDA” means the Company’s consolidated net income before interest income and expense, provision for income taxes, depreciation and amortization, calculated in accordance with US generally accepted accounting principles, then in effect, and in accordance with the currently employed accounting policies, methods and practices employed by the Company.  For the avoidance of doubt, expense calculations hereunder shall include, but not be limited to, restructuring expenses, expenses for payment 

2

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

hereunder or expenses under any equity compensation arrangement or plan.

		
	N.
	“Financial Targets” are the financial targets of the Company established by the Board for the Fiscal Year as described in Section 5 and set forth in Exhibit A attached hereto.

		
	O.
	“Fiscal Year” means the Company’s fiscal year beginning January 1, 2012 and ending December 31, 2012.

		
	P.
	“Management Committee” consists of the Company’s (i) CEO and (ii) Chief Financial Officer.

		
	Q.
	“Minimum Financial Target(s)” shall have the meaning set forth in Exhibit A attached hereto.

		
	R.
	“Named Executive Officer” or (“NEOs”)  means any officer of the Company deemed by the Company as of the last day of 2012 to be  a “named executive officer” of the Company as defined in Item 402(a) of Regulation S-K under the Securities Act of 1933 and the Securities Exchange Act of 1934, each as amended.

		
	S.
	“Non-Exempt Employee” means an employee who receives hourly wages as determined under the Fair Labor and Standards Act and the wage and hours law of the applicable state.  

		
	T.
	“Parent” means any parent corporation of the Company within the meaning of Section 424(e) of the Code.

		
	U.
	“Claw Back” is a compensation recovery method, provided under the Plan to recover all (or a portion) of a prior Bonus Award (i) based on correction or restatement of the Company’s audited financial statements or other factor affecting Financial Targets, or (ii) in the event that any Participant engages in acts or omissions that would result in a termination for Cause.

		
	V.
	“Revenue” means the Company’s Fiscal Year revenue in accordance with the currently employed accounting policies, methods and practices employed by the Company (consistent with U.S. GAAP) and the preparation of its consolidated financial statements and its Budget.

		
	W.
	“Subsidiary” means any subsidiary corporation of the Company within the meaning of Section 424(f) of the Code.

		
	X.
	“Target Bonus Percentages” represent a percentage of each Participant’s Eligible Earnings, designated by position or job level as a target Bonus Award set forth in Exhibit B attached hereto, as applicable.

3

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

		
	3.
	    ELIGIBILITY

In order to be eligible to participate in the Plan and receive a Bonus Award, a Participant must be a full-time active employee and working in a bonus eligible position for at least ninety (90) consecutive days during that Fiscal Year. “Full-Time” is defined as working thirty-five (35) or more hours per week, and have executed all required Company documents.  Employees of subsidiaries that the Company has acquired or may acquire during the Fiscal Year shall not be deemed Participants under the Plan unless specifically designated.  Contingency workers, including, without limitation, temporaries, part-time employees, contractors, consultants and outsourced work teams are not eligible for participation in the Plan.  Employees who transfer into or out of a Bonus Award eligible position during the Fiscal Year will be eligible for a prorated Bonus Award as described in Section 4 below as long as all other criteria under this Plan are met.  In order to be eligible to participate in the Plan and/or to receive any payout, Participants will not be able to participate simultaneously in the Company’s Sales Incentive Plan or any other incentive plans.  To the extent that there is any conflict between this Plan and the Company’s Sales Incentive Plan or other incentive plans, this Plan will govern.

		
	•
	Good Standing:  Participants must be actively employed and in good standing (and otherwise in compliance with the Company’s policies and procedures) on the actual bonus pay date in order to receive a payout.  Participants placed on a performance improvement plan or in corrective action status as a result of poor performance during the Fiscal Year, but that return to “Good Standing” status prior to the bonus payment date will only be eligible for a prorated incentive payout for that Fiscal Year at the discretion of the Management Committee.  If the employee’s status returns to “Good Standing” in the new year, eligibility for full participation in the Plan will be reinstated for the new year going forward, but the employee will not be entitled to a Bonus Award for any period while not in “Good Standing”.  As a condition of the receipt of any Bonus Award, the Participant shall be required to certify (or shall be deemed to have certified) at the time of receipt in a manner acceptable to the Company that the Participant is in compliance with the terms and conditions of the Plan and that the Participant has not engaged in, and does not intend to engage in, any acts or omissions that may result in the termination of Participant’s employment by the Company for Cause.

		
	•
	Forfeiture of Bonus Award:  If a Participant’s employment is terminated for any reason in the Fiscal Year, the Participant will not accrue or otherwise be entitled to any bonus award payment.  If a Participant’s employment is terminated for any reason with or without Cause in the year succeeding Fiscal Year, the Participant will not be entitled to a bonus award payment if the termination date is prior to the date Bonus Awards are actually disbursed, except as may otherwise be provided by the Compensation Committee in its sole and absolute discretion.  Bonus Awards are not considered accrued or earned until they are approved by the Compensation Committee and are actually paid by the Company.  Consequently, a Participant whose employment with the Company is voluntarily or involuntarily terminated for any reason with or without Cause prior to the 

4

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

actual Bonus Award payment date will be deemed ineligible for payment of the Bonus Award.

		
	•
	Sales Incentive Plan:  Without exception, Sales Representatives are not eligible under this Plan, however, they may be eligible under the Company’s Sales Incentive Plan.  “Sales Representatives” means an employee whose primary function is directly engaged in “selling” the Company’s products and services to its customers.

		
	•
	Other Cash Incentives and/or Plans:   Without exception, Participants will not be eligible to receive any cash incentive other than those approved by Compensation Committee.

		
	•
	Acquired Employees: Without exception, employees acquired through any acquisition after the effective date of this Plan shall not be eligible under this Plan.

Participation in this Plan is at the Company’s discretion and the Compensation Committee may, at its sole and absolute discretion, decide to alter, modify, amend or terminate the Plan.

		
	4.
	    PRORATED BONUS AWARDS

A Participant will earn a Bonus Award based on Eligible Earnings for the time period the Participant is actively and continuously employed full-time in an eligible position during the Fiscal Year subject to meeting the eligibility requirements under Section 3.

		
	•
	New Hires and Rehires:  The Bonus Award will be based on Eligible Earnings during the Fiscal Year.  Since Eligible Earnings accounts for time employed and in good status in any given Fiscal Year, a Participant initially hired on July 1st for example would have Eligible Earnings calculated from July 1st through the end of the Fiscal Year.  In the case of rehires, there is no credit for prior service and the rehire date must occur on or before October 3rd in order for the Participant to be eligible under the Plan for the Fiscal Year.

		
	•
	Leaves of Absence:  Time taken during a leave of absence results in a reduction in Eligible Earnings and a corresponding reduction in potential Bonus Awards consistent with the length of time on leave of absence.  Furthermore, payments of Bonus Awards are not considered earned and payable unless and until the Participant returns to work, with the exception of military leave.  If the leave of absence lasts nine months or more during the Fiscal Year, then the Participant will not have met the 90-day eligibility required to earn a bonus for that Fiscal Year.

		
	•
	Promotions and Demotions:  If a Company action results in a Participant’s movement from one bonus-eligible position to another bonus-eligible position (with either a higher or lower bonus target) or an increase or decrease in bonus target, then a prorated Bonus Award will be calculated.  The Bonus Award will be calculated using Eligible Earnings for the applicable time periods that the different bonus percentages were in effect.  However, if a Participant is both promoted and later demoted during the Fiscal Year, the Participant’s entire bonus eligibility and bonus target percent will be determined by the lower grade.

5

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

		
	•
	Move from Bonus-Eligible Position to a Non-Bonus Eligible Position:  The Bonus Award will be calculated based upon Eligible Earnings and the applicable bonus percentage while in a bonus-eligible position as long as the Participant was in the position for a minimum of ninety (90) consecutive days during the Fiscal Year.  

		
	•
	Move from Non-Bonus-Eligible Position to a Bonus-Eligible Position:  The Bonus Award will be calculated based upon Eligible Earnings and the applicable bonus percentage while in the bonus-eligible position as long as the Participant was in the eligible position for a minimum of ninety (90) consecutive days during the Fiscal Year.  

		
	•
	Acquired Employees: Without exception, employees acquired through any acquisition shall not be eligible for a prorated Bonus Award under this Plan.

		
	5.
	FINANCIAL TARGETS AND MINIMUM FINANCIAL TARGETS

The Financial Targets established for the Plan consist of EBITDA, and Revenue amounts approved by the Compensation Committee for the Fiscal Year.  The Company must achieve the Minimum Financial Targets set forth in Exhibit A and consisting of the EBITDA and Revenue amounts approved by the Compensation Committee for the Fiscal Year in order for any payout to occur under the Plan.  

The Financial Targets and Minimum Financial Targets for the Plan Year are set forth in Exhibit A.  Notwithstanding the Financial Targets set forth in Exhibit A, for the purpose of using such Financial Targets to calculate any Bonus Award hereunder, the Plan shall exclude the effect that any acquisition may have on either EBITDA or Revenue. The Management Committee in consultation with the Compensation Committee will, subject to Company’s achievement of Minimum Financial Targets, create separate bonus pools for Mobile Marketing, Enterprise and Carrier business units to be allocated by the Management Committee once such allocation between the business units is approved by the Compensation Committee. 

The Board will consider, in its sole discretion at any time prior to the final determination of Bonus Awards, the impact on Participants of extraordinary or non-reoccurring events, changes in applicable accounting rules or principles, changes in the Company’s methods of accounting, changes in applicable law, changes due to consolidation, acquisitions or reorganization affecting the Company and its subsidiaries or such other material change in the Company’s business and whether to increase, decrease, otherwise adjust actual performance measures, targets, or payout ranges used hereunder or eliminate a Bonus Award if such change(s) is/are desirable in the interests of equitable treatment of the Participants and the Company.  The Management Committee will implement such change(s) for immediate incorporation into the Plan.   

		
	6.
	COMPUTATION AND DISBURSEMENT OF FUNDS

Company performance will be assessed and measured after the end of the Fiscal Year in order to determine annual Bonus Pool funding and Bonus Awards.  Subject to achievement 

6

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

of the Minimum Financial Targets set forth in Exhibit A and the other terms and conditions of the Plan, Bonus Pool funding and Bonus Awards will be determined by the Company’s performance relative to the Financial Targets also set forth in Exhibit A and in the case of the discretionary component set forth in clause (iii) of Exhibit A, will be subject to the sole and absolute discretion of the Compensation Committee.  In the event the Company fails to achieve the Minimum Financial Targets, then Participants will not receive a Bonus Award for the Fiscal Year for EBITDA and Revenue components of the Bonus Award; provided, however, the Compensation Committee may in its discretion still award Bonus Awards related to discretionary component set forth in clause (iii) of Exhibit A.    

The calculation of EBITDA and Revenue will be based upon the Company’s audited financial statements for the Fiscal Year, subject to review and approval by the Board in its sole discretion.  Without exception, unaudited financials will not be used to measure achievement of the Financial Targets or the Minimum Financial Targets.  

As set forth in greater detail in Exhibit A, the Company will provide differentiated Bonus Awards based on business unit and individual performance.  It will execute Bonus Awards inside of the Bonus Pool funding thresholds defined inside this Plan as approved by the Compensation Committee.  The Management Committee shall make recommendations to the Compensation Committee for the allocation of the Bonus Pool between the business units

As soon as practical after the close of the Fiscal Year, the Company’s Chief Financial Officer will calculate the Company’s actual audited achieved performance relative to the Financial Targets, any business unit targets, and the proposed Bonus Awards under the Plan.  The proposed Bonus Award, a list of eligible Participants and their Eligible Earnings will be presented to the Compensation Committee by no later than sixty (60) days following the end of the Fiscal Year and once approved by the Compensation Committee, the Bonus Award will be paid to all Participants by March 31st of the calendar year following the Fiscal Year for which the Bonus Awards are earned.  If the approval from the Compensation Committee occurs after March 31st of the following Fiscal Year, then the Bonus Award payouts will occur as soon as practical following approval, but no later than June 30th of the calendar year following the Fiscal Year for which the Bonus Awards are earned.  If prorated Bonus Awards are granted, then such Bonus Awards will be paid in the same manner at the same time as all the other Bonus Award payouts.

Notwithstanding anything to the contrary in this Plan, if the Compensation Committee determines, in its sole and absolute discretion, that calculations underlying the Financial Targets, including but not limited to mistakes in the Company’s audited financial statements for the Fiscal Year, were incorrect, then the Compensation Committee may (i) adjust Bonus Awards (upward or downward); or (ii) initiate a Claw Back and recover from any Participant, and such Participant shall pay over to the Company, an amount equal to the cash value of any Bonus Award granted under the Plan.

Notwithstanding anything to the contrary in this Plan, in the event that any Participant 

7

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

engages in acts or omissions that would result in a termination for Cause during the twenty-four (24) month period commencing on the date a Bonus Award is paid under the Plan, the Company shall be entitled to initiate a Claw Back and recover or offset against other compensation from the Participant at any time during such twenty-four (24) month period, and the Participant shall pay over to the Company, an amount equal to the cash value of such Bonus Award.

Income, employment and any other applicable taxes will be withheld from any Bonus Award payments required under the Plan to the extent determined by the Company in accordance with applicable law and remitted to the appropriate tax authority.

7.     TARGET BONUS PERCENTAGES
Target Bonus Percentages by position or job level are provided in Exhibit B. 

8.     INDIVIDUAL PERFORMANCE DISCRETIONARY PAYOUT
Subject to the achievement of the Minimum Financial Targets and the availability of the Bonus Pool and the Discretionary Pool, as applicable, such availability to be determined in the Compensation Committee’s sole and absolute discretion, Participant’s discretionary component of actual payout % as set forth in Exhibit A will be determined based on Fiscal Year individual performance and achievement of Company goals.  The variations (i.e., increases or decreases from the Target Bonus Percentages set forth in Exhibits B, as applicable) in Participants’ Bonus Awards that result from adjustments to the discretionary component of actual payout % based on individual performance shall not result in any increase in the aggregate Bonus Pool or Discretionary Pool available to all eligible Participants.

The Management Committee will determine 50% of the discretionary component of actual payout % based on individual performance for each Participant (other than the CEO and CFO) and may adjust such Participant’s Bonus Award in accordance with the terms and conditions of the Plan. The Compensation Committee will determine 50% of the discretionary component of actual payout % based on individual performance for each Participant and may adjust such Participant’s Bonus Award in accordance with the terms and conditions of the Plan.  The Compensation Committee, in its sole and absolute discretion, will determine the entire discretionary component of actual payout % based on individual performance for the CEO and CFO.

9.    ADMINISTRATION
Subject to Sections 3, 5 and 6, the Management Committee will have the authority to administer and make all decisions and exercise all rights of the Company with respect to this Plan, including, the authority (i) to determine eligibility hereunder; (ii) related to rules and regulations for the administration of the Plan; and (iii) to decide any questions and settle controversies and disputes with employees that may arise in connection with the Plan.  For the avoidance of doubt, the Compensation Committee will have the sole authority to interpret the provisions of the Plan, including, without limitation, determination of Financial Targets, funding of the Bonus Pool, oversight of discretionary portions of Bonus Awards and 

8

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

evaluation of individual performance.  The Management Committee will provide the Compensation Committee, no less than once during the Fiscal Year, a summary of significant recurring questions, controversies and disputes (if any) that may have arisen in connection with the Plan during the preceding Fiscal Year.  The Compensation Committee will have the authority to rely upon any reports prepared by the auditors and conclusively determine whether Participants have earned Bonus Awards hereunder.  The members of the Board and Compensation Committee will not be liable for any actions or determinations made with respect to their duties under this Plan.

In the event of a claim or dispute brought forth by a Participant, the decision of the Management Committee as to the facts in the case and meaning and intent of any provision of the Plan, or its application, will be final, binding, and conclusive.  In the case of claims or disputes brought by a Participant that is a member of the Management Committee or a Named Executive Officer, such decisions will be made by the Compensation Committee.

10.     GENERAL PROVISIONS
A Participant’s rights under the Plan will not be assignable, either voluntarily or in-voluntarily by way of encumbrance, pledge, attachment, level or charge of any nature (except as may be required by state or federal law).

In addition to the payment of Bonus Awards to Participants under the Plan, the Compensation Committee retains the sole and absolute discretion to approve an additional discretionary pool to award additional cash bonuses to Participants in recognition of the Company’s achievement of such qualitative or quantitative performance goals as determined by the Compensation Committee.

Nothing in the Plan will require the Company to segregate or set aside any funds or other property for the purpose of paying any portion of a financial award.  No Participant, beneficiary or other person will have any right, title or interest in any amount awarded under the Plan prior to the payment of such award to him or her, or in any property of the Company or its subsidiaries.

Participation in this Plan will not confer upon any Participant any right to continue in the employ of the Company nor interfere in any way with the right of the Company to terminate any Participant’s employment at any time.  The Company is under no obligation to continue the Plan in future fiscal years.

9

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

EXHIBIT A

Plan Financial Targets

The Financial Targets for the Fiscal Year will be as follows (the “Financial Target(s)”):
EBITDA: [*****]
REVENUE: [*****]

Minimum Financial Targets
No payout will be made to Participants unless the Company achieves (i) (A) in the case of Participants other than Named Executive Officers, a minimum EBITDA of 80% of the aforementioned Financial Target for EBITDA and (B) in the case of Participants who are Named Executive Officers, a minimum EBITDA of 90% of the aforementioned Financial Target for EBITDA and (ii) a minimum Revenue of 95% of the aforementioned Financial Target for Revenue (clauses (i) and (ii) together, the “Minimum Financial Target(s)”).  

Bonus Pool
Subject to achievement of the Minimum Financial Targets and the other terms and conditions of the Plan, the Compensation Committee will in its sole and absolute discretion establish the Bonus Pool from funds designated in the Budget at a value targeted to equal the sum of all Bonus Awards to be made under the Plan.

Bonus Awards
Subject to achievement of the Minimum Financial Targets and the other terms and conditions of the Plan, the Bonus Awards for Participants other than Named Executive Officers will equal, and the Bonus Awards for Participants who are Named Executive Officers will equal:

(x) Participant’s Target Bonus Percentage multiplied by Eligible Earnings

multiplied by

(y) Payout % calculated as the sum of clauses (i), (ii), and (iii) below:

		
	(i)
	30% of payout % will be based on EBITDA as follows:

Actual EBITDA below Minimum Financial Target
		
	•
	In the case of Participants other than Named Executive Officers, EBITDA payout % will be 0% if actual EBITDA achieved is below 80% of the Financial Target for EBITDA.

		
	•
	In the case of Participants who are Named Executive Officers, EBITDA payout % will be 0% if actual EBITDA achieved is below 90% of the Financial Target for EBITDA.  

Actual EBITDA at or above Minimum Financial Target
		
	•
	Solely in the case of Participants other than Named Executive Officers, EBITDA payout % will be 30% if actual EBITDA achieved equals or exceeds 80% of the Financial 

10

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

Target for EBITDA, but is less than 90% of the Financial Target for EBITDA; and an additional payout % of 3% for each whole percent that actual EBITDA exceeds 80% of the Financial Target for EBITDA, but is less than 90% of the Financial Target for EBITDA.
		
	•
	In the case of Participants other than Named Executive Officers, EBITDA payout % will be 60% if actual EBITDA achieved equals or exceeds 90% of the Financial Target for EBITDA, but is less than 100% of the Financial Target; and an additional payout % of 4% for each whole percent that actual EBITDA exceeds 90% of the Financial Target for EBITDA, but is less than 100% of the Financial Target for EBITDA.

		
	•
	In the case of Participants who are Named Executive Officers, EBITDA payout % will be 60% if actual EBITDA achieved equals or exceeds 90% of the Financial Target for EBITDA, but is less than 100% of the Financial Target for EBITDA; and an additional payout % of 4% for each whole percent that actual EBITDA exceeds 90% of the Financial Target for EBITDA, but is less than 100% of the Financial Target for EBITDA. 

Actual EBITDA at or above Financial Target
		
	•
	For all Participants, EBITDA payout % will be 100% if actual EBITDA achieved is equal to 100% of the Financial Target for EBITDA.  

		
	•
	For all Participants, for each additional 3% of actual EBITDA achieved beyond 100% of the Financial Target for EBITDA, the EBITDA payout % will increase by 5%.  

		
	•
	Under no circumstance will EBITDA payout % for any Participant exceed 150%. 

Illustrative Table for other than Named Executive Officers:
	
		
	% of Financial  
Target Achieved
	EBITDA
Payout %

	<80%
	—%

	>=80%
	30%

	>=90%
	60%

	>=100%
	100%

	>=115%
	125%

	>=130%
	150%

11

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

Illustrative Table for Named Executive Officers:
	
		
	% of Financial 
                    Target Achieved
	EBITDA  
                  Payout %

	<90%
	—%

	>=90%
	60%

	>=100%
	100%

	>=115%
	125%

	>=130%
	150%

		
	(ii)
	30% of payout % will be based on Revenue as follows:

		
	•
	Revenue payout % will be 0% if actual Revenue achieved is below 95% of the Financial Target for Revenue.  

		
	•
	Revenue payout % will be 60% if actual Revenue achieved exceeds 95% but is less than 100% of the Financial Target for Revenue.  

		
	•
	Revenue payout % will be 100% if actual Revenue achieved is equal to 100% of the Financial Target for Revenue.  

		
	•
	For each additional 1% of actual Revenue achieved beyond the Financial Target for Revenue, the Revenue payout % will increase by 5%.  

		
	•
	Under no circumstance will Revenue payout % exceed 150%. 

Illustrative Table:
	
		
	% of Financial 
Target Achieved
	Revenue  
Payout %

	<95%
	—%

	>=95%
	60%

	>=100%
	100%

	>=105%
	125%

	>=110%
	150%

and

		
	(iii)
	Availability of 40% of payout % to be allocated as follows: the Management Committee will determine 50% of this pool for all employees other than members of the Management Committee; and 50% of this pool   (i.e., 20%) to be allocated in the sole and absolute discretion of the Compensation Committee (together, this portion of the Bonus Pool, if any, the “Discretionary Pool”). It being understood that the Compensation Committee will determine the allocation of the Discretionary Pool for members of the Management Committee. If the Compensation Committee decides in its sole and absolute discretion to fund the Discretionary Pool, actual payout % allocated from this clause (iii) to any 

12

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

Participant is discretionary and will be made as set forth in Section 8 of the Plan.  The Compensation Committee will consider various financial metrics and quantitative metrics including, without limitation, cost of capital, market conditions and competitive landscape.

For the avoidance of doubt, for Participants other than Named Executive Officers, actual payout % allocated for clause (iii) above is discretionary and will be made as set forth in Section 8 of the Plan.

13

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant 
to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to 
denote where omissions have been made. The confidential material has been filed separately with the Securities and 
Exchange Commission. 

EXHIBIT B

Motricity Target Bonus Percentages by Job Title

Target Bonus Percentages by position or job level are as follows:

	
		
	Position / Job Level
	  Target %

	Chief Executive Officer
	75%

	President Mobile Marketing
	70%

	President Enterprise
	50%

	President Carrier
	50%

	Chief Financial Officer
	60%

	VP/SVP
	[*****]

	Director/Senior Director
	[*****]

	Manager/Senior Manager
	[*****]

	Individual Contributors
	[*****]

	Support (Non-Exempt Employees)
	[*****]

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]